India’s ‘Cautious’ View Dulls Sanofi Hopes For Early Dengvaxia Launch

An early rollout of Sanofi Pasteur’s dengue vaccine in India is looking less likely with a senior functionary of the health ministry telling Scrip why India needs to take a “cautious view” on the product’s licensure in the country, at least for now. Sanofi, though, has sought the “best regulatory solution” that can facilitate access to the product.

Mosquito

India is unlikely to clear Sanofi Pasteur ’s dengue vaccine, Dengvaxia, in a hurry and the government would prefer a “cautious” approach given certain safety concerns in young children and the risk of indiscriminate use of the product in the country, among other issues.

Dr Soumya Swaminathan, secretary, department of health research, Ministry of Health and Family Welfare and director general, Indian Council for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip